Trials / Completed
CompletedNCT04994301
Evaluation of Lung T1-MRI in Pediatric Cystic Fibrosis Patients
Lung T1 MRI Assessments of Children with CF Initiating Trikafta Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 56 (actual)
- Sponsor
- University Hospitals Cleveland Medical Center · Academic / Other
- Sex
- All
- Age
- 5 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
In this observational study, the investigators evaluate the sensitivity of T1-MRI to identify lung perfusion changes in pediatric patients with CF (age = 6-11) before and after initiating FDA-approved Trikafta therapy. The investigators compare these Lung T1 MRI assessments (% Normal lung perfusion) to currently best-available assessments of lung function in CF patients (i.e., MBW (LCI( and Spirometry (FEV1 % Predicted).
Detailed description
This is a prospective study with 3 study visits to evaluate the utility of Magnetic Resonance Imaging (MRI) and clinical lung function assessments to detect changes in Cystic Fibrosis (CF) patients before and after administration of the FDA-approved Trikafta therapy. The 3 study visits include: Visit 1: Before starting Trikafta Visit 2: 3 months from start of Trikafta Visit 3: 6 months from start of Trikafta Along with the clinical assessments (MBW and Spirometry), all participants will undergo an MRI scan of the lungs to generate quantitative lung T1 maps. The investigators will compare the lung T1 MRI (% Normal Lung Perfusion) to Multiple Breath Washout (LCI) and spirometry (FEV1 % Predicted) as methods to assess lung changes with administration of Trikafta. The investigators will obtain additional clinical assessments from participant's medical records. This is a multi-site study involving 3 sites.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Lung T1 MRI | Evaluation of lung T1 MRI to Assess Lung Disease |
Timeline
- Start date
- 2020-12-15
- Primary completion
- 2023-12-15
- Completion
- 2023-12-15
- First posted
- 2021-08-06
- Last updated
- 2025-02-27
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04994301. Inclusion in this directory is not an endorsement.